Auckland Cancer Society Research Centre, School of Medical Sciences, University of Auckland, Auckland, New Zealand.
Maurice Wilkins Centre for Molecular Biodiscovery, University of Auckland, Auckland, New Zealand.
PLoS Comput Biol. 2018 Oct 24;14(10):e1006469. doi: 10.1371/journal.pcbi.1006469. eCollection 2018 Oct.
Multicellular tumour spheroids capture many characteristics of human tumour microenvironments, including hypoxia, and represent an experimentally tractable in vitro model for studying interactions between radiotherapy and anticancer drugs. However, interpreting spheroid data is challenging because of limited ability to observe cell fate within spheroids dynamically. To overcome this limitation, we have developed a hybrid continuum/agent-based model (ABM) for HCT116 tumour spheroids, parameterised using experimental models (monolayers and multilayers) in which reaction and diffusion can be measured directly. In the ABM, cell fate is simulated as a function of local oxygen, glucose and drug concentrations, determined by solving diffusion equations and intracellular reactions. The model is lattice-based, with cells occupying discrete locations on a 3D grid embedded within a coarser grid that encompasses the culture medium; separate solvers are employed for each grid. The generated concentration fields account for depletion in the medium and specify concentration-time profiles within the spheroid. Cell growth and survival are determined by intracellular oxygen and glucose concentrations, the latter based on direct measurement of glucose diffusion/reaction (in multilayers) for the first time. The ABM reproduces known features of spheroids including overall growth rate, its oxygen and glucose dependence, peripheral cell proliferation, central hypoxia and necrosis. We extended the ABM to describe in detail the hypoxia-dependent interaction between ionising radiation and a hypoxia-activated prodrug (SN30000), again using experimentally determined parameters; the model accurately simulated clonogenic cell killing in spheroids, while inclusion of reversible cell cycle delay was required to account for the marked spheroid growth delay after combined radiation and SN30000. This ABM of spheroid growth and response exemplifies the utility of integrating computational and experimental tools for investigating radiation/drug interactions, and highlights the critical importance of understanding oxygen, glucose and drug concentration gradients in interpreting activity of therapeutic agents in spheroid models.
多细胞肿瘤球体捕获了许多人类肿瘤微环境的特征,包括缺氧,并代表了一种可用于研究放射治疗和抗癌药物相互作用的实验上易于处理的体外模型。然而,由于在球体中动态观察细胞命运的能力有限,解释球体数据具有挑战性。为了克服这一限制,我们开发了一种用于 HCT116 肿瘤球体的混合连续体/基于代理的模型 (ABM),该模型使用可以直接测量反应和扩散的实验模型(单层和多层)进行参数化。在 ABM 中,细胞命运被模拟为局部氧、葡萄糖和药物浓度的函数,这些浓度由求解扩散方程和细胞内反应来确定。该模型是基于晶格的,细胞占据嵌入在更粗网格中的 3D 网格上的离散位置;为每个网格使用单独的求解器。生成的浓度场考虑了培养基的消耗,并指定了球体内部的浓度-时间曲线。细胞生长和存活由细胞内氧和葡萄糖浓度决定,后者首次基于葡萄糖扩散/反应的直接测量(在多层中)。ABM 再现了球体的已知特征,包括总生长率、对氧和葡萄糖的依赖性、周围细胞增殖、中心缺氧和坏死。我们扩展了 ABM 来详细描述电离辐射与缺氧激活前药 (SN30000) 之间的缺氧依赖性相互作用,再次使用实验确定的参数;该模型准确地模拟了克隆形成细胞杀伤在球体中的作用,而包括可逆细胞周期延迟是解释联合辐射和 SN30000 后球体生长延迟的关键。该球体生长和响应的 ABM 示例说明了集成计算和实验工具来研究辐射/药物相互作用的实用性,并强调了理解氧、葡萄糖和药物浓度梯度在解释治疗剂在球体模型中的活性的重要性。